Cyproterone Acetate Tablets is an anti-androgen preparation. Cyproterone Acetate Tablets are indicated for reducing male hypersexuality; prostate cancer that cannot be surgically treated; severe masculinization symptoms in women, such as very severe hirsutism, androgen-dependent severe hair loss leading to baldness (severe androgenic alopecia), often accompanied by severe acne and/or seborrhea. Precautions: 1. Contraindicated in pregnancy, lactation, liver disease, history of gestational jaundice or persistent pruritus, history of gestational herpes, Dubin-Johnson syndrome, Rotor syndrome, history or presence of liver tumor (not due to metastatic prostate cancer), wasting disease (excluding non-surgical prostate cancer), severe chronic depression, history or presence of thromboembolic conditions, severe diabetes mellitus with vascular changes, sickle cell anemia. 2. Careful consideration of the risks and benefits is necessary in each case before using this drug in prostate cancer patients with a history of thromboembolic disease, sickle cell anemia, or severe diabetes mellitus with vascular changes. 3. Use with caution in patients who require high levels of attention for their occupation (e.g., drivers, machine operators) as this drug may cause fatigue, decreased energy, and may affect the ability to concentrate. 4. The libido-reducing effect of this drug may be weakened by the anti-inhibitory effects of alcohol. 5. This drug should not be administered before the end of puberty as it cannot be excluded that it may have adverse effects on physical growth and the unstable endocrine function axis. 6. Regular liver function, adrenal cortex function, and red blood cell count tests should be performed during treatment. 7. Use with caution in diabetic patients as the need for oral antidiabetic agents or insulin may change. 8. As with other sex steroids, benign and malignant liver changes have been reported in individual cases. In very rare cases, liver tumors may lead to life-threatening intra-abdominal bleeding. Therefore, appropriate diagnosis and treatment should be performed if abnormal upper abdominal discomfort occurs and does not resolve spontaneously within a short period of time. 9. A thorough general and gynecological examination (including breast and cervical cytology smears) should be performed before starting treatment. 10. Pregnancy must be excluded in women of reproductive age. If irregular bleeding occurs within 3 weeks of starting the drug during combined treatment, the drug should not be stopped. However, if bleeding is excessive, necessary investigations should be performed.
